B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

This study is testing B7-H3 CAR-T cell therapy — immune cells engineered to attack a specific protein found on brain tumor cells — in patients with recurrent glioblastoma, the most aggressive type of brain tumor, that has come back after initial treatment. **You may be eligible if...** - You are 18–75 years old and have been diagnosed with WHO Grade IV glioma (glioblastoma), confirmed as IDH wild-type - Your tumor has come back after standard treatment (first recurrence) and surgery is being considered - You have adequate blood counts, kidney, liver, and heart function - Your overall condition allows for surgery (Karnofsky Performance Score ≥ 60) **You may NOT be eligible if...** - Your tumor is in its first occurrence (not yet recurrent) - You have significant organ dysfunction (heart, liver, kidneys) - You are on high doses of steroids (more than 4 mg decadron per day) - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.